All of these data have led physicians to treat RA patients who experience treatment failure with one anti-TNFα agent (due to either inefficacy or toxicity) by switching to a second anti-TNFα agent, although the clear-cut benefits of switching are unknown because no controlled trial has ever been conducted. Here, TNF is linked to rheumatoid arthritis.